Reference 2018-684

REF:           2018-684

Subject:       Trust Zoledronic acid coding

 

Request:

Question 1

What is the OPCS code in your Trust for the delivery of Zoledronic acid 5 mg for the treatment of osteoporosis in post-menopausal women and adult men at increased risk of fracture?

 

Question 2

What is the corresponding HRG code that would relate to the OPCS code from Information request 1 for the outpatient delivery of Zoledronic acid 5 mg for the treatment of osteoporosis in post-menopausal women and adult men at increased risk of fracture in your Trust?

 

Question 3

What is the OPCS code in your Trust for the delivery of Zoledronic acid 4 mg for the prevention of skeletal related events in adult patients with advanced malignancies involving bone or tumour-induced hypercalcaemia?

 

Question 4

What is the corresponding HRG code that would relate to the OPCS code from Information request 3 for the outpatient delivery of Zoledronic acid 4 mg for patients with advanced malignancies involving bone in your Trust?

 

 

Response:

It is not possible to identify the use of this drug through coding.

Visitor restrictions

To protect you and our staff during the current outbreak of Covid-19 we’ve put in place significant restrictions on hospital visitors.

Full details of these can be found on our website.

We would like to thank you for your understanding and helping us stop the spread of Covid-19.

Read More

Stay Home. Protect the NHS. Save Lives.

Close